阳光诺和：STC008注射液I期临床试验正在顺利开展

Core Viewpoint - Yangguang Nuohuo's STC008 injection is the first domestic drug under research for the treatment of cancer cachexia, with ongoing Phase I clinical trials showing promising interim data and no major safety issues reported [2] Group 1: Clinical Trial Progress - The Phase I clinical trial of STC008 is progressing smoothly, with interim data meeting predefined clinical objectives [2] - The timeline for advancing to Phase III clinical trials will be determined based on the complete data from Phase I, optimization of the trial protocol, and regulatory communications [2] - The company is committed to accelerating clinical work and will disclose trial progress to the market in accordance with legal and regulatory requirements to ensure investor awareness [2]